~~<i id='E05F5DF9BB'><strike id='E05F5DF9BB'><tt id='E05F5DF9BB'><pre id='E05F5DF9BB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：explore 2025-10-01 00:48:32 - browse：25163

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： 5 to watch: Tech startups trying to solve health care's staffing crisis

explore

focus

hotspot

knowledge

focus

AdobeHospitals,pharmacies,andotherhealthcareprovidersaregettingstuckinaninsuranceprocessinglogjamaft

WSS

With competition flaring, obesity drug hits goal in liver disease study

Medicare inequities exacerbate Puerto Rico’s health disparities

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

6 phony surgeries that take placebo to the extreme

The Harvard botanist who searched for psychedelics in the Amazon

hotspot

focus

explore

Guidelines to prevent youth baseball injuries need more muscle

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

At least 13 dead in Texas as scorching temps continue

In utero gene editing: an explainer

In age of alternative facts, a scholarly course on calling out crap

With competition flaring, obesity drug hits goal in liver disease study

Tori Bowie and the unacceptable rates of Black maternal death

Health AI adoption puts security, privacy startups on investors' radar

Jerome Adams on the need for new antivirals for Covid

Orchard's therapy for neuron disease in children wins FDA approval

focus

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Intermittent fasting comes with a heart risk? Not so fast

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Baby aspirin cuts fat buildup in liver disease patients, in small study

hotspot

hotspot

knowledge

focus